SXShuang Xiao

Shuang Xiao

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Shuang Xiao has a total of 8 co-authors. Here are the top co-authors by number of shared publications:

  • Bowen Li

    Gastric Cancer Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing, P. R. China

    1 shared publication
  • Gui-Fang Qu

    Department of Oncology, Hunan Provincial People's Hospital and the First Affiliated Hospital of Hunan Normal University , Changsha , People's Republic of China; and Key Laboratory of Study and Discovery of Small Targeted Molecules of Hunan Province, Changsha, Hunan, People's Republic of China

    1 shared publication
  • Huaxin Duan

    Department of Oncology, Hunan Provincial People's Hospital, Changsha, China

    1 shared publication
  • Jing Miao

    School of Pharmaceutical Sciences and Institute of Materia Medica, Xinjiang University, Urumqi 830017, China

    1 shared publication
  • Linghua Tan

    School of Safety Science and Engineering, Nanjing University of Science and Technology, Nanjing 210094, China

    1 shared publication
  • Luting Wang

    Shanghai Institute of Materia Medica Chinese Academy of Sciences 555 Zuchongzhi Rd. Shanghai 201203 China

    1 shared publication

Latest Publications

  • Open Access

    Comparative Study of Camel Milk from Different Areas of Xinjiang Province in China

    by Jing Miao, Shuang Xiao, Jun Wang

    Food Science of Animal Resources (Food Sci. Anim. Resour.) is an international, peer-reviewed bimonthly journal publishing original research and reviews on basic and applied aspects of the use of animal resources including the meat, egg, dairy, and edible insect/worm products. Food Sci. Anim. Resour. is published and distributed by the Korean Society for Food Science of Animal Resources.


  • Open Access

    TCF21 inhibits tumor-associated angiogenesis and suppresses the growth of cholangiocarcinoma by targeting PI3K/Akt and ERK signaling

    by Hua-Xin Duan, Bo-Wen Li, Xin Zhuang, Lu-Ting Wang, Qian Cao, Ling-Hua Tan, Gui-Fang Qu, Shuang Xiao

    Tumor-associated angiogenesis plays a critical role in the pathogenesis of cholangiocarcinoma (CCA). In this study, we examined the biological effects and molecular mechanisms of transcription factor 21 (TCF21) on CCA-associated angiogenesis. TCF21 expression was compared between 15 pairs of peritumor normal tissues and CCA tissues and also between normal bile duct epithelial cells and two CCA cell lines (QBC-939 and TFK-1) using real-time PCR and Western blot. With the use of both CCA cell lines as the model system, we stably expressed TCF21 by lentiviral transduction (Lv-TCF21). In vivo, we monitored xenograft growth from different CCA cells, measured tumor-associated angiogenesis by histological analysis, and determined the expressions and circulatory levels of VEGFA and PDGF-BB by immunohistochemistry and ELISA, respectively. In vitro, we assessed the effects of conditioned medium collected from different CCA cells on the viability, migration, and tube formation of endothelial cells and explored the significance of phosphatidylinositol 3-kinase/protein kinase B (PI3K/Akt), as well as ERK1/2 signaling in this process. TCF21 was significantly downregulated in CCA tissues or cell lines. Ectopic expression of TCF21 in CCA cells inhibited xenograft growth or tumor-associated angiogenesis in vivo and targeted the expression and secretion of proangiogenic factors, VEGFA and PDGF-BB. In vitro, the conditioned medium collected from Lv-TCF21 CCA cells significantly reduced the viability, migration, and tube formation of endothelial cells. On the molecular level, the targeting of PI3K/Akt and ERK1/2 signaling mediated the anti-angiogenic activity of TCF21. TCF21 presents growth-inhibitory and anti-angiogenic activities, and thus the elevation of TCF21 expression may provide therapeutic benefits for CCA. NEW & NOTEWORTHY Transcription factor 21 (TCF21) is downregulated in cholangiocarcinoma (CCA) tissues or cells. TCF21 inhibits the growth of xenografts derived from CCA cells. TCF21 suppresses in vivo tumor-associated angiogenesis. TCF21 targets expression and production of proangiogenic factors from CCA cells. The targeting of phosphatidylinositol 3-kinase/protein kinase B and ERK1/2 signaling mediates the anti-angiogenesis of TCF21.